Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 142

Results For "NCEs"

3076 News Found

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr
News | July 31, 2025

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities


Wallace Pharmaceuticals appoints Chinmaya Mohanty as VP & Head – Human Resources
People | July 30, 2025

Wallace Pharmaceuticals appoints Chinmaya Mohanty as VP & Head – Human Resources

He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt


Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries
Opinion | July 28, 2025

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production


Syngene International appoints Gaurav Kushwaha as CTO
People | July 28, 2025

Syngene International appoints Gaurav Kushwaha as CTO

Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited


Granules India CEO K V Sitaram Rao resigns
People | July 27, 2025

Granules India CEO K V Sitaram Rao resigns

Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service


Zydus receives tentative approval from USFDA for Ibrutinib tablets
Drug Approval | July 24, 2025

Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad


Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
News | July 24, 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint
Clinical Trials | July 21, 2025

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)